Evaluation of adenosine efficacy in the treatment of ventricular tachycardia

Comparison of the Effectiveness of 6 mg and 12 mg Adenosine in the Treatment of Paroxysmal Supraventricular Tachycardia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190929044919N1

Enrollment

142

Registered

2020-06-16

Start date

2019-03-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal Supraventricular tachycardia. Abnormalities of heart beat

Interventions

Intervention 1: Intervention group 1: a dose of 6 mg of adenosine is used, and in case of non-response, a dose of 12 mg, and again, in case of non-response, a dose of 12 mg is used along with Valsalva

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patient should have informed consent to participate in the study The patient has a Paroxysmal Supraventricular Tachycardia The patient's age is in the range of 70-18 years

Exclusion criteria

Exclusion criteria: The Patient dissatisfaction to participate in the intervention Patient sensitivity to adenosine The patient has first and second degree AV node blocks The patient has sick sinus syndrome The patient has a history of previous seizures and epilepsy

Design outcomes

Primary

Measure	Time frame
Heart rhythm. Timepoint: After injecting the final dose of adenosine. Method of measurement: ECG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Fadaeidashti

Shahid Rajaei Hospital

fadaeedashti@abzums.ac.ir026334570030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026